[CY 222, a very low molecular weight heparin, in the curative treatment of deep venous thrombosis. Apropos of 95 cases. Clinical and phlebographic results].
Efficacy of a very low molecular weight heparin, CY 222, in the treatment of deep venous thrombosis of lower limbs was evaluated in a prospective clinical trial instituted in November 1984. CY 222 was administered as subcutaneous injections of 0.03 ml.kg-1 daily (750 anti-Xa U.kg-1.d-1) as 3 divided doses over a minimum of 10 days. Efficacy was rated as a function of clinical and phlebographic criteria. The group of 95 patients treated was a heterogenious one: 38% medical, 62% surgical, and 48% of the total group had partial interruption of vena cava previous to study. The period between first clinical manifestations of the deep thrombosis and therapy varied between one day and 3 months (mean: 1 1/2 days). Clinical symptomatology significantly and globally regressed in 88% of the patients. Comparisons between phlebographic findings at start and end of treatment are expressed using Arnesen's score (cf. table).
Janvier
G
G
Département d'Anesthésie-Réanimation I, Hôpital Pellegrin-Tripode, Bordeaux.
Dugrais
G
G
Winnock
S
S
Vergnes
C
C
Boisseau
M
M
Broussin
J
J
Serise
J M
JM
Boissieras
P
P
Videau
J
J
Toulemonde
F
F
D004341:Drug Evaluation; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D010690:Phlebography; D013924:Thrombophlebitis / Q000145:classification / Q000000981:diagnostic imaging / Q000188:drug therapy*
D006495:Heparin, Low-Molecular-Weight
Le CY 222, Héparine de trés bas poids moléculaire dans le traitement curatif des thromboses veineuses profondes. A propos de 95 observations. Résultats cliniques et phlébographiques.